Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 16/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3764543 | 0.91 | CCR5 (0.49) | CCR5KCNH2 | |
| SCHEMBL3749978 | 0.89 | CCR5 (0.58) | CCR5KCNH2OPRM1 | |
| SCHEMBL3757893 | 0.88 | CCR5 (0.50) | CCR5KCNH2SIGMAR1OPRM1OPRD1 | |
| SCHEMBL3766010 | 0.87 | CCR5 (0.48) | CCR5KCNH2 | |
| SCHEMBL3755060 | 0.86 | CCR5 (0.43) | CCR5KCNH2SIGMAR1 | |
| SCHEMBL3749922 | 0.85 | CCR5 (0.60) | CCR5KCNH2 | |
| SCHEMBL3767889 | 0.85 | CCR5 (0.48) | CCR5KCNH2 | |
| SCHEMBL3755267 | 0.85 | CCR5 (0.44) | CCR5KCNH2OPRM1OPRD1OPRK1 | |
| SCHEMBL3766176 | 0.84 | CCR5 (0.44) | CCR5KCNH2 | |
| SCHEMBL3763632 | 0.82 | CCR5 (0.46) | CCR5KCNH2OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298366-A1 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | GENZYME CORPORATION (US) | 2010-11-25 | — | — | US | disclosed |
| US-7790747-B2 | Chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2010-09-07 | — | — | US | disclosed |
| US-20090099205-A1 | Chemokine receptor binding compounds | GENZYME CORPORATION | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298366-A1 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | CCR5, CXCR3, CCL5 | CCR5 1/4885KCNH2 4679/4885SIGMAR1 890/4885 |
| US-20090099205-A1 | Chemokine receptor binding compounds | CCR5, CXCR3, CCL5 | CCR5 1/4885KCNH2 4679/4885SIGMAR1 890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.